Apollomics appoints Ya-Chi Huang to board following resignation

Apollomics Inc. (NASDAQ: APLM) announced changes to its board of directors following the resignation of Po-Jen Hsueh on November 16, 2025. The company stated that Hsueh's resignation was not related to any disagreement with the company.

The board appointed Dr. Ya-Chi (Claudia) Huang to fill the vacancy left by Hsueh's departure. Huang will also serve on the company's Audit Committee and Nominating and Corporate Governance Committee, replacing Hsueh in these positions.

Following these changes, Apollomics' board comprises seven members: Hung-Wen (Howard) Chen as Chairman, Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang. Five of the seven directors are classified as independent.

Huang currently serves as Assistant Vice President at Maxpro Ventures, where she leads investment activities. She joined the venture capital firm in 2024 and also serves as a director of AngenMed Therapeutics.

Previously, Huang worked as Investment Manager at Diamond Biofund, a company that completed its IPO on the Taiwan Stock Exchange in 2023. She also held a position as Deputy Manager in the Research Department at Fubon Securities Investment Services, where the company states she evaluated over 150 unlisted biotech companies across Taiwan, China, and Hong Kong.

Huang holds a Ph.D. in Microbiology from National Taiwan University College of Medicine and an M.S. in Biological Sciences from National Sun Yat-sen University. Her doctoral research on Epstein-Barr virus was published in the medical journal Blood.

Apollomics is a clinical-stage biopharmaceutical company focused on oncology therapies. The company's lead program is vebreltinib, a c-Met inhibitor currently in Phase 2 clinical trials for non-small cell lung cancer and other advanced tumors.

You May Also Be Interested In

• Suja Life refinances credit agreement, cuts borrowing spread
• Aveanna Healthcare prices secondary offering at $11.75 per share
• Ocean Power Technologies regains NYSE compliance after late 10-K filing